MS and Demyelinating Disorders

Here's what is coming soon to NeurologyLive.

Researchers analyzed levels of sGFAP in participants from the N-MOmentum study that assessed inebilizumab (Uplizna; Viela Bio) in relapsing-remitting MS.

Alise Carlson, MD, a resident at Cleveland Clinic, detailed the reasons for her study evaluating genetic leukodystrophies and their differences to multiple sclerosis at diagnosis.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 26, 2021.

The Astellas Pharma agent earned an indication for children aged 3 years and older, after its original overactive bladder indication in 2012.

An overview of the NeurologyLive tweet chat honoring Multiple Sclerosis Awareness Month, featuring highlighted contributions from the medical community.

The senior investigator at the National Institutes of Neurological Disorders and Stroke outlined studies on anakinra and tolebrutinib as part of a new phase 2a clinical trial paradigm.

A comparison of various factors considered when treating primary progressive multiple sclerosis versus secondary progressive multiple sclerosis.

The Neuroimmunology Clinical Fellow at the National Institutes of Health discussed the evaluations of 2 therapies in multiple sclerosis that she is partaking in.

Increased disability was independently associated with worse clinical severity including death from COVID-19.

The postdoctoral researcher at Columbia University discussed ways clinicians and patients with multiple sclerosis can take to ease the transition of disclosing their diagnosis.

Join NeurologyLive and Barry Singer, MD, on Twitter to discuss a number of topics regarding multiple sclerosis education and where the disease research is headed.

Fred D. Lublin, MD, leads a discussion about the different classifications of secondary progressive multiple sclerosis, including the relationship between disease activity and progression of disease.

Extrapolated comparisons from the ORATORIO trial suggest that patients with primary progressive multiple sclerosis can experience major delays in confirmed time to wheelchair requirement and disease progression.

The findings were consistent with the established safety profile for eculizumab in other non-neurologic indications, according to study authors.

Here's what is coming soon to NeurologyLive.

The president of the Americas Committee for Treatment and Research in MS shared his perspective on the impact of COVID and the top talks at the ACTRIMS Forum 2021.

The PhD candidate at the neuroimmunology laboratory at Memorial University of Newfoundland discussed the potential of interleukin-1 receptor antagonist as a biomarker in MS disability as well as a therapeutic target.

NeurologyLive’s coverage of ACTRIMS Forum 2021 featured a number of insightful conversations with leading experts in multiple sclerosis care.

Researchers from Pavol Jozef Šafárik University, Košice, Slovakia, found that plasma neurofilament light levels predict no evidence of disease activity status as well as NEDA plus brain volume loss status.

With the COVID era changing social environments and interactions, making sure patients can maintain social connections is as important as ever.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 19, 2021.

The oral S1P1 modulator joins a number of other agents in its class, and has also been submitted to the European Medicines Agency for approval in the treatment of MS.

The neurologist from Massachusetts General Hospital discussed when to prescribe disease-modifying therapy and some challenges in caring for patients with RIS.

Age, sex, EDSS score, and recent methylprednisolone use were all identified as risk factors for developing severe COVID-19.